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Abstract: The ageing of the population—especially in developed countries—has brought on many 
societal challenges and has significantly contributed to the burden on healthcare infrastructures 
worldwide. Elderly persons (aged ≥ 65 years) are at higher risk for developing UTIs, due to a range 
of intrinsic and extrinsic risk factors, and they often delay seeking treatment. A retrospective obser-
vational study was performed regarding the epidemiology and resistance of UTIs in elderly pa-
tients. Identification of the isolates was carried out using VITEK 2 ID/AST and MALDI-TOF mass 
spectrometry. Antibiotic resistance in these isolates was assessed based on EUCAST guidelines, and 
were grouped into the WHO AWaRe (Access, Watch, Reserve) classification of antimicrobials. Dur-
ing the 10-year study period, n = 4214 (421.4 ± 118.7/year) and n = 4952 (495.2 ± 274.6) laboratory-
confirmed UTIs were recorded in inpatients and outpatients, respectively. The causative agents 
showed differentiation among outpatients and inpatients: Escherichia coli (48.14% vs. 25.65%; p = 
0.001), Enterococcus spp. (20.15% vs. 21.52%; p > 0.05), Klebsiella spp. (16.28% vs. 16.26%; p > 0.05), 
Pseudomonas spp. (4.40%vs. 13.36%; p = 0.001); Proteus-Providencia-Morganella group (4.56% vs. 
10.96%; p = 0.001); Candida spp. (0.53% vs. 5.98%; p = 0.001); Citrobacter-Enterobacter-Serratia group 
(1.90% vs. 2.71%; p < 0.05). Significantly higher resistance rates were observed in inpatient isolates 
for many Access and Watch antibiotics compared to isolates of outpatient origin; in addition, re-
sistance rates were higher in these uropathogens compared to the previously recorded rates in the 
region. More care should be taken for the diagnosis and treatment of UTIs affecting elderly patients, 
as they represent a particularly vulnerable patient population. 




Urinary tract infections (UTIs) are one of the commonly encountered infectious pa-
thologies worldwide, with ~120–150 million cases each year, being the most common rea-
son to visit a primary care physician [1]. Community-associated UTIs as well as 
healthcare-associated UTIs represent a major factor of morbidity worldwide. These infec-
tions lead to decreased quality of life in the affected patients and are frequently associated 
with recurrence or sequelae, even if the appropriate antimicrobial therapy was adminis-
tered [2,3]. UTIs also lead to a tremendous economic burden (estimated to be around ~5 
billion US dollars), which corresponds to the burden on the healthcare infrastructure and 
the subsequent loss of productivity due to workplace absence [4,5]. 
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Based on the anatomical site affected, UTIs may be classified as upper UTIs (UUTI or 
pyelonephritis) or lower UTIs (LUTI, which may present as (in decreasing incidence) cys-
titis, urethritis and prostatitis). In a clinical sense, UTIs may be further divided into un-
complicated and complicated UTIs, depending on the presence of factors facilitating bac-
terial colonization in the urinary tract (e.g., a structural abnormality) or decreasing thera-
peutic efficacy [6,7]. Members of the Enterobacterales order are the facultative pathogens 
most commonly implicated as causative agents for UTIs in the general population. These 
microorganisms possess an advantageous mix of physiological adaptability and the rele-
vant virulence factors (such as a polysaccharide capsule, urease enzyme, fimbriae, pili) to 
withstand the sheer forces and to thrive on the urinary epithelium [8]. Overall, Escherichia 
coli (or uropathogenic E. coli [UPEC]) is the most frequently isolated species in UTIs [9]; 
nevertheless, in hospitalized and/or immunosuppressed patients, non-conventional uri-
nary pathogens are increasingly present [10,11]. The antimicrobial therapy of UTIs has 
become increasingly challenging, due to worrying developments in antimicrobial re-
sistance (AMR) worldwide [12]; clinicians are often left with scarce therapeutic choices, as 
multidrug-resistant (MDR) bacteria are progressively more common in both community-
associated and healthcare-associated UTIs [13]. Extended-spectrum β-lactamase (ESBL)-
producing Enterobacterales, carbapenem- and fluoroquinolone-resistant Pseudomonas 
spp. and vancomycin-resistant Enterococcus spp. (VRE) are all important representatives 
of urinary MDR isolates, leading to difficult-to-treat infections [14,15]. 
With the onset of the latest epidemiological transition, the main disease burden has 
gradually shifted towards non-communicable diseases, leading to substantial increases in 
life expectancies [16]. The ageing of the population—especially in developed countries—
has brought on many societal challenges and has significantly contributed to the burden 
on healthcare infrastructures worldwide, as individuals with chronic ailments require life-
long therapy and care [17]. Elderly persons (aged 65 or over) are at higher risk for devel-
oping UTIs, due to a range of intrinsic and extrinsic risk factors, and they often delay 
seeking treatment. Intrinsic risk factors include age-related immunological senescence 
and the presence of underlying conditions leading to immunosuppression (e.g., Type II 
diabetes, malignancy), urinary incontinence, benign prostate hyperplasia, malnourish-
ment and immobility, while extrinsic risk factors include hospitalization, urinary cathe-
terization and chemotherapy [18,19]. The treatment of UTIs in elderly and frail individuals 
is further hindered as the use of many antimicrobial groups is discouraged, due to their 
debilitating adverse events and the pathophysiological features (such as decreased kidney 
and liver function) of these patients [20]. 
To facilitate the selection of appropriate antimicrobial therapy, it has been encour-
aged to develop hospital antibiograms based on available local microbiological data, es-
pecially for infections where empirical therapy is prevalent [21]. Nevertheless, the availa-
ble data on the specific epidemiological characteristics of UTIs in elderly patients is scarce, 
often evaluated only as a consortium of larger population data [22]. Consequently, the 
aim of this study was to report on the resistance rates and epidemiology of UTIs affecting 
patients aged ≥65 years in the southern region of Hungary during a 10-year (2008–2017) 
surveillance period. 
2. Results 
2.1. Demographic Characteristics, Sample Types 
The affected patients presented with the following characteristics: in the outpatient 
group, the median age was 75 years (range: 65–96) with a pronounced female dominance 
(60.3%), while in the inpatient group, the median age was 76 years (65–98), with a pro-
nounced male dominance (71.3%). The detailed age distribution of affected patients is pre-
sented in Table 1. 
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Table 1. Age distribution of the affected patients in the outpatient and inpatient groups (2008–2017). 
Age Range Outpatients (n, %) Inpatients (n, %) 
65–69 yrs 1119 (22.59%) 840 (19.93%) 
70–74 yrs 1101 (22.23%) 919 (21.80%) 
75–79 yrs 1091 (22.03%) 1008 (23.92%) 
80–84 yrs 872 (17.61%) 815 (19.34%) 
85 yrs or older 769 (15.54%) 632 (15.01%) 
During the 10-year study period, n = 4214 (421.4 ± 118.7/year, range: 238–567) and n 
= 4952 (495.2 ± 274.6, range: 220–973) laboratory-confirmed UTIs were recorded in inpa-
tients and outpatients, respectively. The distribution of urine sample types in the two 
groups were the following: for outpatients, voided (midstream) urine samples were the 
most relevant (n = 3769, 76.11%), followed by catheter-specimen urine (n = 1107, 22.35%), 
first-stream urine (n = 28, 0.77%), samples obtained through suprapubic bladder aspira-
tion (n = 20, 0.50%) and samples obtained after prostate massage (n = 8, 0.27%); for inpa-
tients, catheter-specimen urine samples were the most common (n = 2961, 70.27%), fol-
lowed by midstream urine (n = 1190, 28.24%), samples obtained through suprapubic blad-
der aspiration (n = 33, 0.78%) and first-stream urine (n = 30, 0.71%), respectively. 
2.2. Distribution of Relevant Pathogens in the UTIs Affecting Elderly Patients 
The causative pathogens of UTIs in elderly patients—corresponding to the 10-year 
study period—are presented in Table 2 (outpatients) and Table 3 (inpatients). Overall, 53 
and 51 distinct bacterial/fungal species were recorded in the outpatient and inpatient 
group, respectively. In both groups, E. coli was the most commonly isolated urinary path-
ogen; nevertheless, the significance of E. coli showed pronounced variance between the 
two groups (48.14% vs. 25.65%; p = 0.001), showing to be less of a primary uropathogen in 
the inpatient group. Enterococcus spp. and Klebsiella spp. were isolated in similar rates in 
both patient groups (20.15% vs. 21.52%; p > 0.05, and 16.28% vs. 16.26%; p > 0.05, respec-
tively), representing the second and third most common isolate. No relevant differences 
were seen in the isolation rates of Acinetobacter spp. (0.83% vs. 0.33%; p > 0.05), members 
of the Citrobacter-Enterobacter-Serratia [CES] group (1.90% vs. 2.71%; p > 0.05) and Staphy-
lococcus spp. (1.55% vs. 2.25%; p > 0.05). On the other hand, some less commonly isolated 
pathogens were significantly more common in inpatients, such as Candida spp. (0.53% vs. 
5.98%; p = 0.001), members of the Proteus-Providencia-Morganella [PPM] group (4.65% vs. 
10.96%; p = 0.001) and Pseudomonas spp. (4.40% vs. 13.36%; p = 0.001). 
Table 2. Distribution of relevant pathogens from outpatient UTIs affecting elderly patients (2008–2017). 
 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Overall (n, %) 
Acinetobacter spp.  41 0.83 
A. baumannii     3  4  2 3 12 0.24 
A. haemolyticus        1   1 0.02 
A. johnsonii      1 1 2 3 1 8 0.16 
A. junii      1  2 2 2 7 0.14 
A. lwoffii 2  1 1 1   1   6 0.12 
A. nosocomialis        1   1 0.02 
A. pittii      1  1  1 3 0.06 
A. schindleri      1     1 0.02 
A. tjernbergiae        1   1 0.02 
A. ursingii        1   1 0.02 
Burkholderia cepacia 1  1   3     5 0.10 
Candida spp.  26 0.53 
C. albicans   1  1  3 7 2 1 15 0.30 
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C. glabrata       1    1 0.02 
C. krusei          1 1 0.02 
C. parapsilosis        1 3  4 0.08 
C. tropicalis   1 1  2 1    5 0.10 
Citrobacter-Enterobacter-
Serratia group   94 1.90 
C. braakii    1       1 0.02 
C. freundii 1  1   2    2 6 0.12 
C. koseri 1 1  1 1 3 3 3 3 6 22 0.44 
Comamonas testosteroni   1        1 0.02 
E. asburiae      1 1  1  3 0.06 
E. cloacae 3 6 3 2 4 4  8 8 4 42 0.85 
E. hormaechei       4    4 0.08 
E. kobei      1 1 3  1 4 0.08 
Enterococcus spp.  998 20.15 
E. avium      1  1 1  3 0.06 
E. faecalis 58 64 66 41 46 73 109 176 139 188 960 19.39 
E. faecium 2 1  3 3 3 1 6 7 8 34 0.69 
E. gallinarum          1 1 0.02 
Escherichia coli 153 121 201 94 83 275 337 547 438 135 2384 48.14 
Klebsiella spp.  806 16.28 
K. aerogenes 1 1 3 2 1 2 1 3 2 5 21 0.42 
K. oxytoca 5 4 9  4 8 13 13 6 14 76 1.53 
K. pneumoniae 16 48 68 34 29 77 80 106 183 65 706 14.26 
K. variicola          3 3 0.06 
Proteus-Providencia-
Morganella group   226 4.56 
M. morganii   1 2 2 1  3 3 3 15 0.30 
P. hauseri          3 3 0.06 
P. mirabilis 5 2 3 10 14 17 22 33 35 46 187 3.78 
P. vulgaris   3  2  4 2 4  15 0.30 
Ralstonia picketti     1 1     2 0.04 
P. rettgerii        1 1  2 0.04 
P. stuartii          4 4 0.08 
Pseudomonas spp.  218 4.40 
P. aeruginosa 21 19 19 25 20 24 18 20 23 21 210 4.24 
P. putida       1 1 4  6 0.12 
P. stutzeri   1    1    2 0.04 
Raoultella ornythiolitica      1  1   2 0.04 
S. marcescens  1      1 5 1 8 0.16 
Staphylococcus spp.  77 1.55 
S. aureus 3 2 4 2 4  5 9 24 12 65 1.31 
S. hominis 1    2  1    4 0.08 
S. lugdunensis         1  1 0.02 
S. saprophyticus   2  2   2 1  7 0.14 
Stenotrophomonas maltophilia    1    1  1 3 0.06 
Streptococcus agalactiae 4 6 8  2  8 14 16 10 68 1.37 
Ureaplasma urealyticum 1     1 1 1 1  5 0.10 
Overall 278 276 397 220 225 504 621 973 918 542 4952  
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Table 3. Distribution of relevant pathogens from inpatient UTIs affecting elderly patients (2008–2017). 
 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Overall (n, %) 
Achromobacter denitrificans         1  1 0.02 
Acinetobacter spp.  17 0.33 
A. baumannii 1  2  1 1  2 1 2 10 0.24 
A. junii        1 1  2 0.05 
A. pittii        1 1  2 0.05 
Aeromonas salmonicida   1        1 0.02 
Burkholderia cepacia 8 1 2 4 2  2  2 1 22 0.52 
Candida spp.  252 5.98 
C. albicans 4 9 12 3 7 14 26 24 21 42 162 3.84 
C. glabrata  3 1 2 2  4 17 5 8 42 1.00 
C. guilliermondii       2  2  4 0.09 
C. inconspicua    1       1 0.02 
C. kefyr     1 1 1    3 0.07 
C. krusei     3  1 1 1  6 0.14 
C. lusitaniae      4    1 5 0.12 
C. parapsilosis 1    1   5  3 9 0.21 
C. tropicalis 2 2 1  3 2 6 4   20 0.47 
Citrobacter-Enterobacter-
Serratia group  114 2.71 
C. farmeri        1   1 0.02 
C. freundii 2  1 1       4 0.09 
C. koseri  1 1   3 2 3 3 3 16 0.38 
Corynebacterium urealyticum         1  1 0.02 
E. asburiae        1   1 0.02 
E. cloacae 6 6 16 4 5 11 7 3 6 4 68 1.61 
E. kobei        3  3 6 0.14 
E. ludwigii      1  1  2 4 0.09 
Enterococcus spp.  907 21.52 
E. avium         1  1 0.02 
E. faecalis 59 46 58 78 73 100 100 93 109 104 820 19.46 
E. faecium 3 11 5 5 5 11 8 7 19 12 86 2.04 
E. gallinarum          1 1 0.02 
Escherichia coli 61 67 103 110 105 111 147 138 139 100 1081 25.65 
Klebsiella spp.  685 16.26 
K. aerogenes 2 2 3 4 1 1 4 1 1 1 20 0.47 
K. oxytoca 3 2 1 7 4 6 11 8 9 9 60 1.42 
K. pneumoniae 24 32 56 49 57 93 80 67 84 63 605 14.36 
Proteus-Providencia-
Morganella group  462 10.96 
Kocuria kristinae      2 1    3 0.07 
M. morganii 1 1  1  3 2 5 7 5 25 0.59 
Pantoea agglomerans       2    2 0.05 
P. hauseri          1 1 0.02 
P. mirabilis 14 13 25 38 28 48 59 67 51 41 384 9.11 
P. vulgaris 1 5 6 8 2 5 8 3 6 2 46 1.09 
P. rettgerii         2 2 4 0.09 
P. stuartii         1 1 2 0.05 
Pseudomonas spp.  563 13.36 
P. aeruginosa 34 50 48 52 59 59 73 52 62 68 557 13.22 
P. mosselii          1 1 0.02 
P. putida       2 1  2 5 0.12 
S. marcescens 1    2  2  1 7 13 0.31 
Staphylococcus spp.  95 2.25 
S. aureus 5 10 3 11 7 13 7 7 8  71 1.68 
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S. haemolyticus 1     1   1  3 0.07 
S. hominis 1  1 2 3 2     9 0.21 
S. intermedius 1          1 0.02 
S. saprophyticus 1      2    3 0.07 
S. maltophilia  1  1 1 1  2  2 8 0.19 
S. agalactiae  3  3 2 1    2 11 0.26 
Overall 238 266 350 385 392 507 567 526 554 492 4214  
2.3. Antimicrobial Resistance Rates of Bacterial Uropathogens Based on the WHO AWaRe 
Classification 
The rates of antibiotic resistance among urinary pathogens affecting elderly patients 
are presented in Tables 4–9; namely, for outpatient isolates, Tables 4, 6 and 8, while for 
inpatient isolates, Tables 5, 7 and 9, corresponding to the WHO Access, Watch and Re-
serve classification of antibiotics, respectively. Among the Access antibiotics, there were 
significant differences seen between the resistance rates of outpatient vs. inpatient sam-
ples for AMK (0.7% vs. 4.7%; p < 0.05) and NIT (3.6% vs. 30.9%; p < 0.001) in E. coli, AMK 
(6.3% vs. 12.8%; p < 0.05) and GEN (21.9% vs. 31.8%; p < 0.05) in Klebsiella spp., and GEN 
(45.4% vs. 30.3%; p < 0.01) in Pseudomonas spp (Tables 4 and 5). While percentages of re-
sistance were generally higher in the inpatient group for the majority of cases, statistically 
significant differences were not seen for other species-antibiotic pairs. 
Table 4. Percentage of resistant isolates from outpatient UTIs against WHO Access antibiotics. 
 AMK AMP CLI GEN NIT SXT 
Staphylococcus spp. (n = 77) 10.3% (n = 8) 92.2% (n = 71) 33.8% (n = 26) 3.4% (n = 3) 0% (n = 0) 16.9% (n = 13) 
Enterococcus spp. (n = 998) n.r. 1.2% (n = 12) n.r. 29.7% (n = 296) 1.3% (n = 13) n.r. 
Escherichia coli (n = 2384) 0.7% (n = 12) 58.5% (n = 1396) n.r. 8.2% (n = 196) 5.6% (n = 134) 32.9% (n = 784) 
Klebsiella spp. (n = 806) 6.3% (n = 51) n.r. n.r. 21.9% (n = 177) n.r. 30.1% (n = 243) 
Citrobacter-Enterobacter-
Serratia group (n = 94) 5.3% (n = 5) n.r. n.r. 14.9% (n = 14) n.r. 27.7% (n = 26) 
Proteus-Providencia-
Morganella group (n = 226) 3.1% (n = 7) n.r. n.r. 21.7% (n = 49) n.r. 64.1% (n = 125) 
Pseudomonas spp. (n = 218) 21.6% (n = 47) n.r. n.r. 45.4% (n = 99) n.r. n.r. 
Abbreviations: amikacin (AMK), ampicillin (AMP), clindamycin (CLI), gentamicin (GEN), nitrofurantoin (NIT), trime-
thoprim-sulfamethoxazole (SXT), n.r.: not relevant. 
Table 5. Percentage of resistant isolates from inpatient UTIs against WHO Access antibiotics. 
 AMK AMP CLI GEN NIT SXT 
Staphylococcus spp. (n = 95) 16.8% (n = 16) 97.9% (n = 93) 68.4% (n = 65) 10.5% (n = 10) 6.3% (n = 6) 20.0% (n = 19) 
Enterococcus spp. (n = 907) n.r. 2.6% (n = 24) n.r. 39.3% (n = 356) 5.8% (n = 53) n.r. 
Escherichia coli (n = 1081) 4.7% (n = 51) 54.6% (n = 590) n.r. 9.3% (n = 101) 30.9% (n = 335) 25.2% (n = 273) 
Klebsiella spp. (n = 685) 12.8% (n = 88) n.r. n.r. 31.8% (n = 218) n.r. 27.8% (n = 274) 
Citrobacter-Enterobacter-
Serratia group (n = 114) 6.1% (n = 7) n.r. n.r. 17.5% (n = 20) n.r. 28.1% (n = 32) 
Proteus-Providencia-
Morganella group (n = 462) 5.6% (n = 26) n.r. n.r. 14.1% (n = 65) n.r. 64.5% (n = 298) 
Pseudomonas spp. (n = 563) 16.2% (n = 91) n.r. n.r. 30.3% (n = 171) n.r. n.r. 
Abbreviations: amikacin (AMK), ampicillin (AMP), clindamycin (CLI), gentamicin (GEN), nitrofurantoin (NIT), trime-
thoprim-sulfamethoxazole (SXT), n.r.: not relevant (antibiotics affected by intrinsic resistance mechanisms). 
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Rates of methicillin-resistance in S. aureus (inferred from the results of the FOX sus-
ceptibility test: 15.6% vs. 35.8%; p < 0.001), vancomycin-resistance in Enterococcus spp. 
(1.0% vs. 4.6%; p < 0.05) and resistance to III. generation cephalosporins (inferred from the 
results of CEF and CTZ susceptibility results in Enterobacterales (E. coli: 13.1% vs. 14.4%, 
p > 0.05; Klebsiella spp.: 27.7% vs. 43.1%, p < 0.01; CES: 31.9% vs. 34.2%; PPM: 42.0% vs. 
68.4%, p < 0.01), in addition, resistances against other Watch antibiotics are presented in 
Tables 6 and 7. There were significant differences seen between the resistance rates of out-
patient vs. inpatient samples for FOS (5.5% vs. 17.4%; p < 0.01) and TOB (10.8% vs. 27.4%; 
p < 0.01) in Klebsiella spp., TOB (5.3% vs. 14.6%; p < 0.05) for PPM and for TOB (40.6% vs. 
27.5%; p < 0.05), CIP (55.0% vs. 40.1%; p < 0.05) and LEV (56.4% vs. 43.7%; p < 0.05) for 
Pseudomonas spp. Similar to the Access group, resistance rates for Watch antibiotics were 
generally higher in the inpatient group, but statistical significance was only shown in the 
previously mentioned cases. 
As seen in Tables 8 and 9, urinary isolates in the elderly retained susceptibility to 
Reserve antibiotics (no resistant isolate was detected from either outpatient or inpatient 
samples). In addition, MDR and XDR rates of urinary isolates are also represented in these 
Tables: rates of MDR were 19.4% and 40.0% (p < 0.001) in Staphylococcus spp., 1.2% and 
5.4% (p < 0.05) in Enterococcus spp., 16.6% and 16.7% (p > 0.05) in E. coli, 35.9% and 53.7% 
in Klebsiella spp., 31.9% and 31.6% (p > 0.05) in the Citrobacter-Enterobacter-Serratia group, 
49.8% and 69.7% (p < 0.01) in the Proteus-Providencia-Morganella group, and 14.2% and 
27.2% (p < 0.05) in the outpatient and inpatient groups, respectively. Apart from 
Psuedomonas spp. from inpatient origin (0.4%), no XDR isolates were recorded. 
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Table 6. Percentage of resistant isolates from outpatient UTIs against WHO Watch antibiotics. 
 AZI FOX CEF CTZ FEP CIP LEV FOS FAA IMP MER RIF TOB VAN 
Staphylococcus spp. (n = 77) 35.0% 
(n = 27) 
15.6% 
(n = 12) 
n.r. n.r. n.r. 44.1%  
(n = 34) 
44.1%  
(n = 34) 
n.t. 0%  
(n = 0) 
15.6% (n = 12) 15.6% (n = 12) 0%  
(n = 0) 
10.3% 
(n = 8) 
0%  
(n = 0) 
Enterococcus spp. (n = 998) n.r. n.r. n.r. n.r. n.r. 34.1%  
(n = 340) 
34.1%  
(n = 340) 
n.r. n.r. 1.2%  
(n = 12) 
n.r. n.r. n.r. 1.0%  
(n = 10) 
Escherichia coli (n = 2384) n.r. n.r. 13.1%  
(n = 312) 
13.1%  
(n = 312) 
11.9%  
(n = 285) 
40.9%  
(n = 975) 
40.9%  
(n = 975) 
0.2%  
(n = 4) 
n.r. 0%  
(n = 0) 
0%  
(n = 0) 
n.r. 3.5%  
(n = 83) 
n.r. 
Klebsiella spp. (n = 806) n.r. n.r. 27.7%  
(n = 223) 
27.7%  
(n = 223) 
24.7%  
(n = 199) 
48.1%  
(n = 388) 
48.1%  
(n = 388) 
5.5%  
(n = 45) 
n.r. 0.1%  
(n = 1) 
0.1%  
(n = 1) 
n.r. 10.8% 
(n = 87) 
n.r. 
Citrobacter-Enterobacter-Serratia group (n = 94) n.r. n.r. 31.9%  
(n = 30) 
31.9%  
(n = 30) 
22.3%  
(n = 21) 
25.5%  
(n = 24) 
25.5%  
(n = 24) 
5.3%  
(n = 5) 
n.r. 3.2%  
(n = 3) 
1.1%  
(n = 1) 
n.r. 10.6% 
(n = 10) 
n.r. 
Proteus-Providencia-Morganella group (n = 226) n.r. n.r. 42.0%  
(n = 95) 
42.0%  
(n = 95) 
40.3%  
(n = 91) 
58.6%  
(n = 122) 
58.6%  
(n = 122) 
14.6% 
(n = 33) 
n.r. n.r. 0%  
(n = 0) 
n.r. 5.3%  
(n = 12) 
n.r. 
Pseudomonas spp. (n = 218) n.r. n.r. n.r. 12.8%  
(n = 28) 
11.9%  
(n = 26) 
55.5%  
(n = 121) 
56.4%  
(n = 123) 
n.r. n.r. 26.6%  
(n = 25) 
23.4%  
(n = 22) 
n.r. 41.6% 
(n = 94) 
n.r. 
Abbreviations: azithromycin (AZI), cefepime (FEP), cefoxitin (FOX), ceftriaxone (CEF), ciprofloxacin (CIP), ceftazidime (CTZ), fosfomycin (FOS), fusidic acid (FAA), imipenem (IMP), 
levofloxacin (LEV), meropenem (MER), vancomycin (VAN), n.r.: not relevant (antibiotics affected by intrinsic resistance mechanisms); n.t.: not tested. 
Table 7. Percentage of resistant isolates from inpatient UTIs against WHO Watch antibiotics. 
 AZI FOX CEF CTZ FEP CIP LEV FOS FAA IMP MER RIF TOB VAN 
Staphylococcus spp. (n = 95) 72.6% 
(n = 67)
35.8% 
(n = 34) 
n.r. n.r. n.r. 77.9%  
(n = 78) 
77.9%  
(n = 78) 
n.t. 0%  
(n = 0)
35.8% (n = 34) 35.8% (n = 34) 0%  
(n = 0)
27.4%  
(n = 26) 
0%  
(n = 0) 
Enterococcus spp. (n = 907) n.r. n.r. n.r. n.r. n.r. 39.3%  
(n = 356) 
39.3%  
(n = 356) 
n.r. n.r. 2.6%  
(n = 24) 
n.r. n.r. n.r. 4.6%  
(n = 42) 
Escherichia coli (n = 1081) n.r. n.r. 14.4%  




(n = 128) 
30.5%  
(n = 330) 
30.5%  
(n = 330) 
4.7%  
(n = 51) 
n.r. 0.2%  
(n = 3) 
0.2% (n = 3) n.r. 26.1%  
(n = 282) 
n.r. 
Klebsiella spp. (n = 685) n.r. n.r. 43.1%  




(n = 221) 
46.7%  
(n = 320) 
45.7%  
(n = 313) 
17.4%  
(n = 119) 
n.r. 1.3%  
(n = 9) 
1.0% (n = 7) n.r. 27.4%  
(n = 188) 
n.r. 
Citrobacter-Enterobacter-Serratia group (n = 114) n.r. n.r. 34.2%  
(n = 39) 
34.2%  
(n = 39) 
25.4%  
(n = 29) 
17.5%  
(n = 20) 
17.5%  
(n = 20) 
11.4%  
(n = 13) 
n.r. 1.8%  
(n = 2) 
0.9% (n = 1) n.r. 13.2%  
(n = 15) 
n.r. 
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Proteus-Providencia-Morganella group (n = 462) n.r. n.r. 
68.4%  




(n = 316) 
50.8%  
(n = 235) 
50.8%  
(n = 235) 
9.5%  
(n = 44) n.r. n.r. 
0%  
(n = 0) n.r. 
14.6%  
(n = 68) n.r. 




(n = 95) 
40.1%  
(n = 226) 
43.7%  
(n = 246) n.r. n.r. 
23.9%  
(n = 135) 
21.5%  
(n = 121) n.r. 
27.5%  
(n = 155) n.r. 
Abbreviations: azithromycin (AZI), cefepime (FEP), cefoxitin (FOX), ceftriaxone (CEF), ciprofloxacin (CIP), ceftazidime (CTZ), fosfomycin (FOS), fusidic acid (FAA), imipenem (IMP), 
levofloxacin (LEV), meropenem (MER), vancomycin (VAN), n.r.: not relevant (antibiotics affected by intrinsic resistance mechanisms); n.t.: not tested. 
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Table 8. Percentage of resistant isolates from outpatient UTIs against WHO Reserve antibiotics and rates of MDR and 
XDR isolates. 
 CFT COL QPD LIN TIG MDR XDR 
Staphylococcus spp. (n = 77) 0% (n = 0) n.r. 0% (n = 0) 0% (n = 0) 0% (n = 0) 19.4% (n = 15) 0% (n = 0) 
Enterococcus spp. (n = 998) n.r. n.r. n.r. 0% (n = 0) 0% (n = 0) 1.2% (n = 12) 0% (n = 0) 
Escherichia coli (n = 2384) n.r. 0% (n = 0) n.r. n.r. n.r. 16.6% (n = 396) 0% (n = 0) 
Klebsiella spp. (n = 806) n.r. 0% (n = 0) n.r. n.r. n.r. 35.9% (n = 289) 0% (n = 0) 
Citrobacter-Enterobacter-
Serratia group (n = 94) 
n.r. 0% (n = 0) n.r. n.r. n.r. 31.9% (n = 30) 0% (n = 0) 
Proteus-Providencia-
Morganella group (n = 226) 
n.r. n.r. n.r. n.r. n.r. 49.8% (n = 112) 0% (n = 0) 
Pseudomonas spp. (n = 218) n.r. 0% (n = 0) n.r. n.r. n.t. 14.2% (n = 31) 0% (n = 0) 
Abbreviations: ceftaroline-fosamil (CFT), colistin (COL), linezolid (LIN), tigecycline (TIG), quinpristin-dalfopristin (QPD); 
n.r.: not relevant (antibiotics affected by intrinsic resistance mechanisms); n.t.: not tested. 
Table 9. Percentage of resistant isolates from inpatient UTIs against WHO Reserve antibiotics and rates of MDR and XDR 
isolates. 
 CFT COL QPD LIN TIG MDR XDR 
Staphylococcus spp. (n = 95) 0% (n = 0) n.r. 0% (n = 0) 0% (n = 0) 0% (n = 0) 40.0% (n = 38) 0% (n = 0) 
Enterococcus spp. (n = 907) n.r. n.r. n.r. 0% (n = 0) 0% (n = 0) 5.4% (n = 49) 0% (n = 0) 
Escherichia coli (n = 1081) n.r. 0% (n = 0) n.r. n.r. n.r. 16.7% (n = 180) 0% (n = 0) 
Klebsiella spp. (n = 685) n.r. 0% (n=0) n.r. n.r. n.r. 53.7% (n=367) 0% (n=0) 
Citrobacter-Enterobacter-
Serratia group (n=114) 
n.r. 0% (n = 0) n.r. n.r. n.r. 31.6% (n = 36) 0% (n = 0) 
Proteus-Providencia-
Morganella group (n = 462) 
n.r. n.r. n.r. n.r. n.r. 69.7% (n = 322) 0% (n = 0) 
Pseudomonas spp. (n = 563) n.r. 0% (n = 0) n.r. n.r. n.t. 27.2% (n = 153) 0.4% (n = 2) 
Abbreviations: ceftaroline-fosamil (CFT), colistin (COL), linezolid (LIN), tigecycline (TIG), quinpristin-dalfopristin (QPD); 
n.r.: not relevant (antibiotics affected by intrinsic resistance mechanisms); n.t.: not tested. 
3. Discussion 
UTIs are the third most common (after respiratory tract infections and gastrointestinal 
infections) types of infections in human medicine, affecting a significant amount of patients 
worldwide, irrespective of age, gender and socio-economic status [23]. Nevertheless, elderly 
individuals are particularly sensitive to the development of UTIs, due to age-related physi-
ological changes, emergence of bacteriuria, high prevalence of comorbidities and frequent 
hospitalization of these patients [18,19]. The prevalence of UTIs among the community-
dwelling elderly patients is estimated at 12–29 per 100 person years at risk, while this num-
ber is 44–58 per 100 person years at risk for residents of long-term care facilities [24]. Physi-
cians may treat patients with UTIs, if they are armed with the knowledge of the etiological 
spectrum and resistance rates of urinary pathogens, specific for the healthcare setting, geo-
graphical location and relevant patient population [25]. These data may also be useful in 
decisions for empirical therapy, if the identification of the pathogen has already been carried 
out, while susceptibility data are still pending [26]. However, the creation and maintenance 
of such patient-specific antibiograms for UTIs may be difficult, as there are several patient 
populations (e.g., males, children, elderly, patients affected by a kidney transplant) for 
which limited epidemiological data are available [27]. 
As a part of our study, the characterization of 9166 UTIs (4952 outpatient and 4214 in-
patient cases)—affecting individuals 65 years of older—was performed, corresponding to a 
10-year study period (2008–2017) in the southern region of Hungary, using the WHO 
AWaRe selection criteria (a tool intended to be used to support pharmaco-epidemiological 
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studies and drug use monitoring) [28]. Our initial hypotheses were that UTIs affecting el-
derly patients will present with a more diverse distribution of pathogens, and that relevant 
uropathogenic bacteria will show higher rates of resistance, compared to the rates observed 
in the general population. While E. coli was the most commonly implicated pathogen in both 
outpatients and inpatients, the ratio of E. coli isolates in inpatients was significantly less nu-
merous compared to outpatients, which may be explained by the fact that many uncommon 
bacteria were also isolated in notable numbers from inpatient samples. The relevance of en-
terococci should not be underestimated, as they represented >20% of isolates, and the treat-
ment options for these infections may be especially scarce in cases of extensive resistance. 
The increasing incidence of enterococci with the advanced age of the patients has been ver-
ified by other major studies previously; in addition, there has been evidence showing that 
patients affected by diabetes and/or metabolic disorder are significantly more susceptible to 
infections caused by Gram-positive cocci [12,22,29,30]. Additionally, the more precise iden-
tification method used in the second part of the study period (2013–2017) may also have had 
a role in the increased detection of enterococci, as it differentiates these isolates more suc-
cessfully from other streptococci, which would have been dismissed as contaminants or col-
onizers by the clinical microbiologist and/or physician. 
In addition, members of the PPM group, Pseudomonas spp. accounted for >10% while 
Candida spp. accounted for >5% of isolates among inpatients. The management of can-
diduria and Candida urinary tract infections is often a controversial topic, as the relation-
ship between the presence of these yeasts and the patient’s complaints may not be verified 
[31]; nevertheless, yeasts as true urinary pathogens are far more common in older patients, 
and hospitalized, severely debilitated individuals [32]. This was first verified in the 1980s, 
when Platt et al. reported that 26.5% of catheter-associated UTIs (defined as >105 microor-
ganisms) are caused by Candida spp [33]. In addition, there have been reports on the in-
creasing prevalence of non-albicans Candida species (e.g., C. glabrata, C. guilliermondi, C. 
krusei, C. parapsilosis and C. tropicalis among others), which has important therapeutic con-
sequences, as non-susceptibility to the first-line treatment fluconazole is high [34]. The 
emergence of Pseudomonas spp. and members of the PPM group in UTIs should also raise 
concerns, as these bacteria have a plethora of intrinsic resistance mechanisms, which fur-
ther limit the available treatment options [35,36]. 
Significant differences were observed in the resistance rates among inpatient and out-
patient isolates for several Access and Watch antibiotics; in addition, our study has high-
lighted the worrisome developments in the levels of MDR in these isolates, irrespective of 
origin. Resistance rates of outpatient isolates were shown to be very similar to an earlier 
report in the same region, which has assessed the susceptibility rates of isolates originat-
ing from patients visiting the Emergency Department [37]. Overall, the non-susceptibility 
rates of elderly isolates were comparable to or somewhat higher than (2–10%) previously 
reported rates in UTIs in the same geographical region [9]; higher rates of resistance were 
mostly seen for nitrofurantoin, fosfomycin, trimethoprim-sulfamethoxazole, all relevant 
antibiotics in the therapy of uncomplicated UTIs [38]. Similarly higher rates of resistance 
were seen for the fluoroquinolones across all analyzed species, a drug group, which has—
until recently—been extensively used by primary care physicians in Hungary to treat UTIs 
[39]. Interestingly, resistance rates to III. generation cephalosporins, trimethoprim-sulfa-
methoxazole and the fluoroquinolones in E. coli were lower (by 5–15%) in isolates origi-
nating from the elderly, compared to previously published reports [9]. 
Since the early 2000s, the prevalence of Enterobacterales resistant to III. generation 
cephalosporins (most frequently due to the production of ESBLs) in UTIs has shown an 
increasing an trend worldwide, which has led to the substantial use of carbapenem anti-
biotics to manage these infections [40,41]. However, carbapenem-resistance (CR) in uri-
nary pathogens is emerging threat, which severely limits the therapeutic arsenal of clini-
cians to provide safe antimicrobial therapy, often forcing them to use older drugs with a 
disadvantageous side effect profile (e.g., colistin) or newer, significantly more expensive 
antibiotics (e.g., meropenem/vaborbactam, if appropriate) with limited availability and 
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clinical experience [42–44]. Among the members of Enterobacterales, CR is most common 
in K. pneumoniae and E. coli, while among non-fermenters, non-susceptibility of A. bau-
mannii complex and P. aeruginosa have also shown worrisome developments [45]. A ret-
rospective (2014–2019) study by Shields et al. found that the prevalence of CR pathogens 
in UTIs was 4.4% from assessing the data of >700 US hospitals [46]. Additionally, their 
study noted that CR-UTIs were more common in patients aged over 65, and were associ-
ated with adverse clinical outcomes (higher rates of subsequent bacteremia, longer hospi-
tal stay and recurrence). Due to the reportedly high prevalence of Enterococcus spp., one 
should prepare for the possibility of encountering vancomycin-resistant variants (VRE), 
with a global prevalence ranging between 0–18% (5–30% in Intensive Care Units) [47]: 
while in case of E. faecalis, susceptibility to ampicillin (and other β-lactams) and amino-
glycosides is usually retained, E. faecium is highly resistant to these drugs, therefore guide-
lines recommend therapy with either linezolid or daptomycin, depending on the clinical 
situation [48]. 
The number of available reports on the epidemiology of UTIs in the elderly is scarce. 
Hrbacek et al. reported on the resistance of uncommon urinary isolates, mainly members 
of the CES (Citrobacter-Enterobacter-Serratia) and PPM (Proteus-Providencia-Morganella) 
groups, Acinetobacter and Pseudomonas [10]: the overall prevalence of these pathogens was 
4.65% in a 9-year (2011–2019) study period, with male patients being disproportionally 
more affected (76.8%); the mean age of patients were 70.3 and 69.2 years for males and 
females. The majority (50–80%) of the surveyed isolates were resistant to aminopenicillins 
and I-II. generation cephalosporins, while resistance rates to III. generation cephalospor-
ins, fluoroquinolones, aminoglycosides, carbapenems, nitrofurantoin and SXT were 
around 5–15%, 20%, 6–33.3%, 10%, 90% and 10–30%, respectively [10]. The increased di-
versity of urinary pathogens in patients with advanced age was further verified by the 
findings of Kot et al., noting the increasing importance of Enterococcus spp. and P. mirabilis 
as uropathogens in Polish patients [7]. In a rare study focusing on the 10-year epidemiol-
ogy of suprapubic bladder aspirates, Gajdács et al. found that around half of the samples 
originated from patients aged ≥65; out of these samples, almost one-third (32.6%) were 
culture-positive (defined as ≥102 CFU/mL), with Enterococcus spp., E. coli and Klebsiella 
spp. being the three most common isolates [49]. Interestingly, this study also found strict 
anaerobic bacteria (namely Finegoldia magna, Peptococcus niger, and Peptinophilus indolicus) 
as relevant pathogens. 
Ioannou et al. performed a 3-year retrospective study, during which n = 204 UTIs 
were recorded in a Greek patient population (mean age: >83 years, 61.3% female). The 
principal pathogen was E. coli (40.5%, among which 16.9% were ESBL-producers), while 
P. mirabilis, P. aeruginosa and enterococci were all among the more commonly isolated 
species [18]. In their cohort, 25% of patients had Type II diabetes, 43.6% presented with 
sepsis, and the overall mortality rate was 17.8%. In an observational study by Artero et 
al., the relevance of simultaneous bacteremia during a UTI was observed in elderly Span-
ish patients (n = 333, mean age: 81.6); in this study, E. coli was the major urinary pathogen 
(66.9%). Setting in-hospital mortality as their primary outcome measure, they concluded 
that the presence of bacteremia (in 41.1% of cases) was not associated with longer hospital 
stays or higher mortality rates (8.8% vs. 9.7%) [50]. Kofteridis et al. assessed the differences 
in the outcomes of pyelonephritis in older adults with or without diabetes: their cohort 
consisted of 88 patients with diabetes and 118 controls, with a median age of 74 years in 
both groups. The most common etiological agents was E. coli, but Candida spp. was five 
times more common in patients with diabetes [51]. Compared to the control group, pa-
tients with diabetes had worse outcomes in every outcome measure studied (fever, hos-
pitalization, mortality). In a long-term epidemiological study (2001–2018) López-de-An-
drés et al. highlighted the importance of age and comorbidities (Type 2 diabetes) in the 
development of UTIs: the incidence of these infections was 2.14-times higher in non-dia-
betic males aged 75–84 years, compared to patients aged 18–50 years; while in patients 
affected by this metabolic disease, UTI incidence was 17.54-times higher in males and 
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15.47-times higher in females aged 75–84 years, compared to patients aged 18–50 years 
[52]. In a recent study by Serretiello et al., a five-year (2015–2019) study was conducted on 
the epidemiology of UTIs in an Italian university hospital: out of the 46,382 patients en-
rolled in their study, 21.3% (n = 9896) were positive for microbial growth, with a 62.2% 
female patient population. Among the uropathogens, E. coli (48.9%) and K. pneumoniae 
(14.9%) were the most numerous, while 13.8% were Gram-positive cocci, with E. faecalis 
being a representative of the group (9.7%). The authors concluded that Klebsiella spp. and 
E. faecalis showed the highest levels of resistance in the region, while carbapenems (for 
Gram-negative bacteria), vancomycin (for Gram-positive bacteria) and WHO Reserve an-
tibiotics are still safe and effective therapeutic alternatives [53]. 
On the basis of our results, and the results of other study groups described previ-
ously, more care should be taken for the diagnosis and treatment of UTIs affecting elderly 
patients, as they represent a particularly vulnerable patient population [18,24]. The use of 
various antiseptic solutions (e.g., povidone-iodine, chlorhexidine gluconate) before in-
dwelling urinary catheterization may provide significant benefits in reducing the number 
of healthcare-associated UTIs [54,55]. Further investigations—particularly to develop spe-
cific antibiograms with the aim of aiding local antimicrobial stewardship initiatives—are 
recommended, and clinicians should be aware of the possible hallmarks of treatment fail-
ure in these patients [56]. 
4. Materials and Methods 
4.1. Study Site, Study Design, Data Collection 
The present retrospective observational study was to assess the burden of UTIs in 
elderly patients in the southern region of Hungary, including the epidemiology and re-
sistance rates of these infections. Based on the data of the Hungarian Central Statistical 
Office (KSH), the population of Hungary is estimated to be 9,730,772 (population density 
~ 105.1/km2), out of which, 20.31% (estimated to be around 1,976,666) are citizens aged 65 
or older; males are underrepresented among the country’s elderly (38.30%) [57]. Our 
study was performed at the Department of Microbiology (previously: Institute of Clinical 
Microbiology), Albert Szent-Györgyi Health Center (University of Szeged), which is a ~ 
1800-bed primary- and tertiary-care teaching hospital, serving as the major health care 
facility in the region for ~400,000 patients [58]. The present study was carried out using 
data collected representing a time period of 10 years (1 January 2008–31 December 2017) 
at the Department of Microbiology, which is the principal clinical microbiology laboratory 
of the Health Center. Data collection was performed via an electronic record search in the 
laboratory information system, corresponding to urine samples (originating from patients 
aged ≥ 65 years) positive for relevant pathogens, according to the criteria below. 
Samples with clinically significant colony counts for suspected urinary pathogens 
(105 < colony forming units [CFU]/mL; nevertheless, this was subject to interpretation, 
based on the information provided on the request forms for microbiological analysis and 
relevant clinical guidelines) were included in the data analysis [9,14]. Only the first isolate 
per patient was included in the study, while isolates with different antibiotic-susceptibil-
ity patterns were considered as different individual isolates [9,14]. In addition, patient 
data were also collected, that were limited to demographic characteristics (age and sex) 
and inpatient/outpatient status. Affected patients were grouped into distinct age groups, 
based on the criteria of the WHO World (WHO 2000–2025) standard population [59]. 
The study was designed and performed in accordance with the Declaration of Helsinki. 
4.2. Identification of Bacterial Isolates 
The workup of urine samples arriving at the Department of Medical Microbiology (pre-
viously: Institute of Clinical Microbiology) was carried out based on the guidelines pub-
lished by the Hungarian Ministry of Health [60]. Namely, 10 µL of each uncentrifuged urine 
sample was cultured on a UriSelect chromogenic agar plate (Bio-Rad, Berkeley, CA, USA) 
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with a calibrated loop, according to the manufacturer’s instructions. Plates were incubated 
for 24–48 h aerobically at 37 °C. If the growth of relevant pathogens was observed in 
significant colony counts, plates were passed on for identification and antimicrobial 
susceptibility testing [9]; in case of yeasts or uncommon pathogens, additional procedures 
were used. In the first five years (2008–2012) of the study, biochemical methods and the 
VITEK 2 ID/AST automated system (bioMérieux, Marcy-l’Étoile, France) were used for 
identification (ID); following 2012, matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) was also introduced into the routine workflow. 
During ID, a MicroFlex MALDI Biotyper (Bruker Daltonics, Bremen, Germany) was used, 
while for spectrum analysis, the MALDI Biotyper RTC 3.1 software and the MALDI 
Biotyper Library 3.1 (Bruker Daltonics, Bremen. Germany) were utilized. During MALDI-
TOF measurements, bacterial cells from overnight cultures were transferred onto a stainless 
steel target via a sterile toothpick. An on-target extraction was performed by adding 1 µL of 
70% formic acid prior to the matrix. After drying at an ambient temperature, the cells were 
covered with 1 µL matrix (α-cyano-4-hydroxy cinnamic acid in 50% acetonitrile/2.5% tri-
fluoro-acetic acid; Bruker Daltonics, Bremen, Germany). Mass spectrometry measurements 
were carried out in positive linear mode across the m/z range of 2 to 20 kDa; for each spec-
trum, 240 laser shots at 60 Hz in groups of 40 shots per sampling area were collected [61]. 
Based on spectra analysis, the system provided a log(score) value, indicating the reliability 
of the MALDI-TOF MS identification: scores < 1.69 showed unreliable identification, 1.70–
1.99 corresponded to probable genus-level identification, 2.00–2.29 corresponded to reliable 
genus-level identification, while a score ≥ 2.30 corresponded to reliable species-level identi-
fication [61]. 
4.3. Antimicrobial Susceptibility Testing of Relevant Isolates 
Antimicrobial susceptibility testing for relevant bacterial pathogens and the 
interpretation of the results was performed based on the recommendations of the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) at the time of 
isolation [62]. Susceptibility data were collected for the following antibiotics (when 
relevant): amikacin (AMK), ampicillin (AMP), azithromycin (AZI), cefepime (FEP), 
cefoxitin (FOX), ceftriaxone (CEF), ceftaroline-fosamil (CFT), ciprofloxacin (CIP), 
clindamycin (CLI), colistin (COL), ceftazidime (CTZ), fosfomycin (FOS), fusidic acid 
(FAA), gentamicin (GEN), imipenem (IMP), levofloxacin (LEV), linezolid (LIN), 
meropenem (MER), nitrofurantoin (NIT), trimethoprim-sulfamethoxazole (SXT), 
tigecycline (TIG), quinpristin-dalfopristin (QPD) and vancomycin (VAN), taking into 
account the intrinsic resistance mechanisms of isolated bacteria [63]. Advanced resistance 
mechanisms (e.g., resistance to III. generation cephalosporins, methicillin-resistance) were 
inferred from results of phenotypic tests [14]. The following strains were used as quality 
controls: Staphylococcus aureus ATCC 29213. Enterococcus faecalis ATCC 29212. Escherichia 
coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853. 
Intermediate results were grouped with and reported as resistant [9,14]. Classification 
of bacterial isolates as multidrug resistant (MDR) or extensively drug resistant (XDR) was 
based on the Magiorakos et al. [64]. Antibiotics were classified as “Access”, “Watch” or “Re-
serve”, based on the World Health Organization (WHO) AWaRe classification 2019 [28]. 
4.4. Statistical Analysis 
Descriptive statistical analysis (including means or medians with ranges and percent-
ages to characterize data) was performed using Microsoft Excel 2013 (Microsoft Corp. 
Redmond, WA, USA). Statistical analyses were performed with SPSS software version 22 
(IBM Corp., Endicott, NY, USA), using the χ2-test, Student’s t-test and Mann–Whitney U 
test. The normality of variables was tested using the Kolmogorov–Smirnov test. p values 
<0.05 were considered statistically significant. 
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4.5. Limitation of the Study 
The present study possesses some limitations, which must be acknowledged: a 
retrospective study design, risk of selection bias (as the study was performed in a tertiary-
care hospital, with a high throughput of severely ill patients); limited clinical data to assess 
the independent risk factors affecting the emergence of UTIs in patients aged ≥ 65 years; 
due to the change in the identification methods in the second part of the study (2013–
2017), the pathogenic spectrum has seemingly broadened, which cannot be verified as 
these methods were initially (2008–2017) not available; not all antibiotics were routinely 
tested during susceptibility testing, therefore those results could not be reported to more 
precisely ascertain MDR/XDR status of the bacteria; and molecular testing was not 
performed to ascertain the exact mechanism of action behind the phenotypic resistance of 
individual isolates. 
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